INPEFA (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023

INPEFA recently approved by FDA for treatment of heart failure

THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients. These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.

“We continue to make progress in establishing access and reimbursement for INPEFA and are pleased by the Express Scripts decision announced today,” said Lonnel Coats, Lexicon’s chief executive officer. “We continue to work toward our goal of broad access to and coverage for INPEFA, with this being the latest of a series of coverage decisions.”

On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

• heart failure or

• type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
  

INPEFA is currently commercially available in the U.S.

About INPEFA (sotagliflozin)

Discovered using Lexicon’s unique approach to gene science, INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose reabsorption by the kidney and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. INPEFA has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.